Field Reimbursement Managers in 2026: How the FRM Role Has Evolved

The Field Reimbursement Manager (FRM) role has always focused on removing barriers between prescribed therapy and the patient who needs it. What has changed dramatically is the nature, scale, and complexity of those barriers.

In 2026, access challenges are more interconnected, more data-driven, and more consequential than they were even five years ago. Payer dynamics have intensified. Distribution models have fragmented. Administrative requirements have expanded. And delays at the point of access now carry greater financial, clinical, and operational implications.

Understanding how the FRM role has evolved, and where it’s headed, matters for anyone responsible for market access strategy, field force design, patient services, or account management.

The Old Model: Reactive Problem-Solving

Historically, the FRM role was largely reactive. A physician prescribed a medication. The pharmacy or office staff encountered a coverage issue. The FRM stepped in to help navigate the prior authorization, appeal a denial, or connect the patient to financial assistance.

This model assumed that most of the access work happened at the point of prescription. The FRM’s value was in troubleshooting individual cases and educating office staff on how to work with payers.

That model still exists in some form. But it’s no longer sufficient.

What Changed: Forces Reshaping the FRM Role

Several forces have converged to reshape the FRM role fundamentally.

• The Inflation Reduction Act reshaped payer economics. The IRA’s provisions, including Medicare drug price negotiation and the $2,000 out-of-pocket cap for beneficiaries, have had cascading effects. While the out-of-pocket cap may increase patient willingness to fill prescriptions, payers are responding aggressively with additional rebates, utilization management tools, and formulary restrictions.
• Utilization management has intensified. Prior authorizations have become more stringent and more frequent. Step therapy requirements, quantity limits, specialty tier placement, and “fail first” requirements add layers of friction.
• Distribution has become more complex. The straightforward “buy and bill” model is no longer universal. Specialty pharmacy requirements, white bagging, and brown bagging have introduced new logistics and reimbursement challenges.
• Site of care shifts have accelerated. Payers and health systems are pushing certain treatments out of hospital outpatient settings and into physician offices, ambulatory infusion centers, or home infusion. Each site of care has different reimbursement structures and operational considerations.
• Health system formularies have added another layer. Beyond payer formularies, IDNs and large medical groups maintain their own drug formularies and protocols. A drug may be covered by insurance but restricted within the health system’s preferred treatment pathways.

The Expanded Role: From Troubleshooter to Access Strategist

Given these changes, the FRM role in 2026 looks more like a strategic access consultant than a reactive problem-solver.

Effective FRMs now engage proactively with high-priority accounts to anticipate access challenges before they affect patients. They help practices build efficient processes for managing administrative requirements. They coordinate with broader account teams, bringing a unique lens on access and reimbursement that informs overall account strategy. And they develop detailed local payer intelligence that national policies don’t capture.

This evolution requires capabilities beyond traditional FRM training: ecosystem knowledge, account planning skills, and the ability to collaborate across functions.

Implications for Organizations

Companies that still think of FRMs primarily as “prior authorization helpers” are underutilizing the role and likely underinvesting in it.

The field reimbursement function sits at the intersection of market access strategy and patient outcomes. When it works well, patients get the therapies they need without unnecessary delays or abandonment. When it doesn’t, the best clinical and commercial work upstream leaks away at the point of access.

Looking Ahead

In 2026, that intersection has become more complicated and more consequential. The FRM role has evolved accordingly—moving from reactive problem-solving toward proactive, strategic engagement. The question is whether organizational structures, processes, and leadership expectations have evolved at the same pace.

WLH Consulting has helped pharmaceutical organizations build and elevate field reimbursement capabilities as the access landscape has grown more complex. To discuss how your FRM function can evolve from troubleshooting to strategic engagement, contact us at wendy@wlhconsulting.com.

References

1. Inflation Reduction Act of 2022 (IRA). Public Law 117-169. Provisions affecting Medicare drug pricing, out-of-pocket caps, and manufacturer obligations.

2. Portch, M. (2024). Interview on pharmaceutical market access evolution and Inflation Reduction Act implications. WLH Consulting, Inc.

3. WLH Consulting, Inc. (2024). Account Management Knowledge Offerings: Buy and Bill – “Follow the Dollar.” Account Management Academy Program.

4. WLH Consulting, Inc. (2024). Account Management Academy: Program assets adapted for Field Reimbursement roles.